Company Analysis

Travere Therapeutics, Inc. (TVTX)

Nasdaq: TVTX · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2008
Grade6.4
◀ Past 5.8● Present 6.9▶ Future 6.4
1 est.

Filings

368 filings since 2017 beside 568 insider forms · Large accelerated filer · read from EDGAR on Nov 13, 2026
Due nextLarge accelerated filer
10-K Annual report for the fiscal year ending Dec 31, 2026Large accelerated filers have 60 days after the fiscal year ends. by Mar 1, 2027
10-Q Quarterly report for the quarter ending Mar 31, 2027Large accelerated filers have 40 days after the quarter ends; quarter ends are taken to the month end. by May 10, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 33 days after the quarter ended. The proxy statement was last filed Apr 6, 2026.

Filings a yearinsider forms included
6094107757794130169
20192020202120222023202420252026

2026 counts to Nov 13, 2026.

Officer or director change (8-K item 5.02): 6 times in the last 36 months, the newest Sep 21, 2026.
Insider forms 568

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Nov 5, 2026 SCHEDULE 13G/A Large holder update, amended
Nov 2, 2026 10-Q Quarterly report Sep 30, 2026
Nov 2, 2026 8-K items 2.02, 9.01 Results released · Current report
Sep 21, 2026 8-K items 5.02, 9.01 Officer or director change · Current report
Aug 14, 2026 SCHEDULE 13G/A Large holder update, amended
Aug 12, 2026 SCHEDULE 13G Large holder notice
Aug 7, 2026 SCHEDULE 13G Large holder notice
Aug 6, 2026 SCHEDULE 13G/A Large holder update, amended
Aug 4, 2026 10-Q Quarterly report Jun 30, 2026
Aug 4, 2026 8-K items 2.02, 9.01 Results released · Current report
Jul 9, 2026 8-K item 5.02 Officer or director change · Current report Jul 6, 2026
Jun 17, 2026 S-8 Employee stock plan registration
Jun 16, 2026 8-K item 5.02 Officer or director change · Current report Jun 12, 2026
Jun 2, 2026 8-K items 1.01, 9.01 Major agreement signed · Current report Jun 1, 2026
May 21, 2026 8-K items 5.02, 5.07, 9.01 Officer or director change; Shareholder vote · Current report May 19, 2026
May 15, 2026 SCHEDULE 13G Large holder notice
May 11, 2026 8-K items 1.01, 2.03, 3.02, 8.01, 9.01 Major agreement signed; New debt or obligation taken on; Shares sold without registration; Other event · Current report May 6, 2026
May 7, 2026 424B5 Shelf offering
May 7, 2026 305B2 Form 305B2
May 7, 2026 FWP Offering communication
May 5, 2026 424B5 Shelf offering
May 4, 2026 10-Q Quarterly report Mar 31, 2026
May 4, 2026 8-K items 2.02, 9.01 Results released · Current report
Apr 30, 2026 SCHEDULE 13G Large holder notice
Apr 14, 2026 8-K item 8.01 Other event · Current report Apr 13, 2026
Apr 6, 2026 ARS Annual report to shareholders Dec 31, 2025
Apr 6, 2026 DEFA14A Extra proxy material
Apr 6, 2026 DEF 14A Proxy statement May 19, 2026
Mar 27, 2026 SCHEDULE 13G/A Large holder update, amended
Feb 19, 2026 10-K Annual report Dec 31, 2025
Feb 19, 2026 8-K items 2.02, 9.01 Results released · Current report
Feb 17, 2026 SCHEDULE 13G/A Large holder update, amended
Feb 17, 2026 SCHEDULE 13G/A Large holder update, amended
Feb 13, 2026 SCHEDULE 13G/A Large holder update, amended
Feb 9, 2026 SCHEDULE 13G Large holder notice
Jan 13, 2026 8-K item 8.01 Other event · Current report
Jan 12, 2026 8-K items 2.02, 9.01 Results released · Current report
Jan 8, 2026 SCHEDULE 13G Large holder notice
Nov 14, 2025 SCHEDULE 13G/A Large holder update, amended
Nov 14, 2025 SCHEDULE 13G/A Large holder update, amended
40 of 368 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton TVTX · research, not advice